University of Michigan

Other

EunGi Kim

Jolanta Grembecka

Tomasz Cierpicki

Szymon Klossowski

Hongzhi Miao

Jing Deng

Hao Li

Trupta Purohit

Dong Chen

Wenbing Chen

Sergei Zari

Yassir Adam

Hyo Je Cho

Christina Howard

Mykhaylo Potopnyk

Huang Huang

Sergii Dudkin

Brian Linhares

Alyssa Winkler

Dymytrii Listunov

Provided herein are small molecule inhibitors of NSD1, NSD2 and/or NSD3 activity, and methods of use thereof for the treatment of disease, including leukemia, breast cancer, osteosarcoma, lung and prostate cancers and other solid tumors as well as other diseases dependent on the activity of NSD1, NSD2 and/or NSD3.

NSD family inhibitors and methods of treatment therewith

Provided herein are small molecules comprising a first domain that binds to ASH1L and a second domain that facilitates ASH1L degradation. In particular, ASH1L-targeting proteolysis targeting chimeras (PROTACs) and methods of use thereof for the treatment of disease (e.g., acute leukemia, solid cancers and other diseases dependent on activity of ASH1L) are provided.

ASH1L degraders and methods of treatment therewith

Provided herein are small molecules that bind to GAS41 and inhibit GAS41 activity, and methods of use thereof for the treatment of cancer.

GAS41 inhibitors and methods of use thereof

Provided herein are small molecules that bind to ASH1L and inhibit ASH1L activity, and methods of use thereof for the treatment of disease, including acute leukemia, solid cancers and other diseases dependent on activity of ASH1L.

ASH1L inhibitors and methods of treatment therewith

Growing community of inventors

Ann Arbor, MI, United States of America

EunGi Kim